Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials

Di Tan; Jia-rui Wu; Xiao-meng Zhang; Shi Liu; Bing Zhang

doi:10.1007/s11655-017-2424-x

Your Location：

Home >

Browse articles >

Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials

Updated：2021-08-27

- Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials
- Chinese Journal of Integrative Medicine Vol. 24, Issue 2, Pages: 156-160(2018)
- Affiliations：
  
  Department of Clinical Pharmacology of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81473547 and No. 81673829)
- DOI：10.1007/s11655-017-2424-x
  CLC：
- Published：2018，
  
  Published Online：28 November 2017，
Scan for full text
Tan, D., Wu, Jr., Zhang, Xm. et al. Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials., Chin. J. Integr. Med. 24, 156–160 (2018). https://doi.org/10.1007/s11655-017-2424-x

Di Tan, Jia-rui Wu, Xiao-meng Zhang, et al. Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials. [J]. Chinese Journal of Integrative Medicine 24(2):156-160(2018)
Tan, D., Wu, Jr., Zhang, Xm. et al. Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials., Chin. J. Integr. Med. 24, 156–160 (2018). https://doi.org/10.1007/s11655-017-2424-x DOI：

Di Tan, Jia-rui Wu, Xiao-meng Zhang, et al. Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials. [J]. Chinese Journal of Integrative Medicine 24(2):156-160(2018) DOI： 10.1007/s11655-017-2424-x.

摘要

To systematically evaluate the effectiveness and safety of Sodium Tanshinone II A Sulfonate Injection (STS) as one adjuvant therapy for treating unstable angina pectoris (UAP). Randomized controlled trials (RCTs) of UAP treated by STS were searched in the China National Knowledge Infrastructure Database (CNKI)

VIP Database for Chinese Technical Periodicals (VIP)

Wanfang Database

the Chinese Biomedical Literature Database (CBM)

Web of Science

the Cochrane Library

Embase

and PubMed

which from inception to January

2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. The results showed that 17 RCTs involving 1

372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine (WM) in the treatment of UAP can obviously improve the total effective rate [risk ratio (RR)=1.31

95% confidence interval (CI) (1.24

1.39)

P<0.0001]

and the total effective rate of electrocardiogram [RR=1.43

95% CI (1.30

1.56)

P<0.0001]

decrease the level of CRP [mean difference (MD)=–3.06

95%CI (–3.85

–2.27)

P<0.00001]

fibrinogen [MD=–1.03

95% CI (–1.16

–0.89)

P<0.00001]

and whole blood high shear viscosity [MD=–0.70

95% CI (–0.92

–0.49)

P<0.00001]. Additionally

the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57

95% CI (1.28

9.94)

P<0.05]. Compared with WM

the combined use of STS was more effective.

Abstract

VIP Database for Chinese Technical Periodicals (VIP)

Wanfang Database

the Chinese Biomedical Literature Database (CBM)

Web of Science

the Cochrane Library

Embase

and PubMed

which from inception to January

95% confidence interval (CI) (1.24

1.39)

P<0.0001]

and the total effective rate of electrocardiogram [RR=1.43

95% CI (1.30

1.56)

P<0.0001]

decrease the level of CRP [mean difference (MD)=–3.06

95%CI (–3.85

–2.27)

P<0.00001]

fibrinogen [MD=–1.03

95% CI (–1.16

–0.89)

P<0.00001]

and whole blood high shear viscosity [MD=–0.70

95% CI (–0.92

–0.49)

P<0.00001]. Additionally

the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57

95% CI (1.28

9.94)

P<0.05]. Compared with WM

the combined use of STS was more effective.

关键词

Sodium Tanshinone II A Sulfonate InjectionChinese Medicineunstable angina pectorisrandomized controlled trialssystematic reviewmeta-analysis

Keywords

Sodium Tanshinone II A Sulfonate InjectionChinese Medicineunstable angina pectorisrandomized controlled trialssystematic reviewmeta-analysis

references

Bai FM. Advances in clinical application of sodium tanshinone ? A sulfonate. Chin Pharm (Chin) 2012;23:2971–2973.

Lv XS. Sodium tanshinone II A sulfonate effects on hemorheology in patients with unstable angina pectoris. Prevent Treat Cardio-Cerebral-Vascular Dis (Chin) 2007;7:190–193.

He WF, Lv Z, Zhang QB. Research progress on tanshinone in pharmacological mechanism of cardiovascular protection. Chin Med Guid (Chin) 2013;10:34–38.

Ji HL, Liu YY, Wu QA. Meta-analysis of efficacy of sodium Tanshinone II A Sulfonate Injection in the treatment of unstable angina pectoris. Chin Pharm (Chin) 2011;22:2665–2667.

Ma XC, Li JX, Xu DM, Deng XQ, Yue GH, Zheng JH. Metaanalysis on effectiveness and safety of Tanshinone II A Sulfonate Sodium Injection in treatment of unstable angina pectoris. World Sci Tech/Mod Tradi Chin Med Mat Med (Chin) 2015;17:1766–1774.

Xu XY, Wu YM, Chen XX, Lin J. Meta-analysis of efficacy and adverse reactions of Sodium Tanshinone II A Sulfonate Injection in the treatment of unstable angina pectoris. Str Pharm J (Chin) 2014;26:114–117.

Ye RG, Lu ZY, eds. Internal medicine. People’s Medical Publishing House; 2004:281–282.

Chinese Society of Cardiology, Editorial Committee on Chinese Journal of Cardiology. Diagnosis and treatment of unstable angina pectoris. Chin J Card (Chin) 2000;28:409-412.

He F, Zhou XL. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Mod Pract Med (Chin) 2014;26: 815–816.

Tan YW, He XB, Zhang ZQ. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Mod J Int Trad Chin West Med (Chin) 2008;17:3768–3769.

Liu HL, Yang XH. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Chin Med Innova (Chin) 2010;7:37.

Song WJ. Sodium Tanshinone II A Sulfonate Injection in adjuvant treatment of coronary heart disease and unstable angina. Chin Heal Indust (Chin) 2011;8:52.

Zhang Y, Cao ZC, Liu BS. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Acta Acad Med Neimongol (Chin) 2013;35:382–384.

Yang N, Ren FX. Sulfotanshinone sodium unstable angina pectoris: a study of clinical application. Mod Chin Doctor (Chin) 2010;48(21):47–49.

Luo WA, Li ML. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Chin Med Pharm (Chin) 2011;1:50.

Ge HZ, Cheng YN, Tan HY. Sodium tanshinone II A sulfonate clinical observation on the treatment of unstable angina pectoris. Chin J Difficult Compli Case (Chin) 2010;9:201–202.

Yuan Gl, Zao JA, Li Y, Gao XM, Yue SM. Sodium tanshinone II A sulfonate curative effect observation of treating coronary heart disease with angina pectoris. Clin Focus (Chin) 2006;21:1347–1348.

Pei X, Chen G. Sodium tanshinone II A sulfonate with Western medicine treat 36 patients with unstable angina. Shaanxi J Traditl Chin Med (Chin) 2009;30:1276–1278.

Xie JB, Xie YG. Sodium Tanshinone II A Sulfonate Injection in the treatment of patients with unstable angina. Chin J Pract Med (Chin) 2011;38:88–89.

Chen G. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Chin J Pharm Economics (Chin) 2013;8(9):63–64.

Ju H. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Jilin Med J (Chin) 2013;34:1475.

Zhang XG, Zhang YM. Observation on the effect of sodium tanshinone II A sulfonate in the treatment of unstable angina pectoris. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2006;4:857–858.

Chen XL, Yang JZ, Xiong HS, Long B. Clinical research of sulfotanshinone sodium in treatment of unstable angina pectoris. Chongqing Med (Chin) 2008;37:168–169.

Zhang W. Clinical observation of Tanshinone Injection in the adjuvant treatment of unstable angina pectoris. China Mod Med (Chin) 2011;18:72–73.

Wang JH. Tanshinone II A treatment of unstable angina clinical study of myocardial protection. Chin Med Mod Dis Education China (Chin) 2010;158–159.

Liu HC, Liu HH. Adverse reactions of Tanshinone II A sodium Sulfonate Injection in treating 18 cases: an analysis of clinical features. Chin J Integrated Traditi Western Med (Chin) 2013;33:1287–1289.

Li LH, Sun ZF, Li XB. Sodium Tanshinone II A Sulfonate Injection analysis of adverse reactions. Practic Pharm Clin Remed (Chin) 2010;55–56.

Sun LE. Analysis of 27 cases of adverse reactions induced by Sulfotanshinone Sodium Injection during year 2010 to 2012 in Shaoxing city. Chin Pharm Affairs (Chin) 2014;28:218–220.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

A systematic review and meta-analysis of type 2 diabetes mellitus treatment based on the “three-typed syndrome differentiation” theory in Chinese medicine

Individual patient data meta-analysis is needed in Chinese medical research

Efficacy and safety of Flos Abelmoschus manihot (Malvaceae) on type 2 diabetic nephropathy: A systematic review

Potassium Dehydroandrographolide Succinate Injection for the treatment of child epidemic parotitis: A systematic review and meta-analysis

Acupuncture Treatment for Post-Stroke Dysphagia: An Update Meta-Analysis of Randomized Controlled Trials

Related Author

No data

Related Institution

Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

China Academy of Chinese Medical Sciences

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases

Division of Infectious Diseases, Chinese PLA Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰